Surfbird Money

Acquisition Closed October 5, 2026

Theravance Biopharma, Inc. acquisition by Zymeworks Inc. (closed): stock options and RSUs

Completed: SEC filings show this deal closed by October 5, 2026. Zymeworks bought Theravance Biopharma for $17.00 per share in cash plus one contingent value right (CVR) per share.

Buyer
Zymeworks Inc.
What holders receive
$17.00 per share in cash plus a contingent value right (CVR)
Agreement signed
June 28, 2026
Shareholder vote
—
Expected closing
in the second half of 2026
Closed
October 5, 2026

How equity awards are treated

Stock optionscashed out
Unvested RSUsconverted, keep vesting on original schedule (likely)
Performance awards (PSUs)mentioned; terms vary

Estimate your payout at $17.00 per share

Options pay the spread between the deal price and the exercise price; options priced at or above $17.00 usually pay nothing. Whether unvested awards pay now or later depends on the treatment above. Before taxes.

What this means for your taxes

  • Shares you own outright are sold for cash at closing. That is a taxable sale: the gain over your cost basis is a capital gain, long-term if you have held the shares more than a year at closing. For shares from vested RSUs, your basis is generally the value already taxed at vesting (it was on your W-2).
  • Options and RSUs paid in cash run through payroll as wages: income tax plus Social Security and Medicare. Employers usually withhold federal income tax at a flat 22%, or 37% on supplemental wages above $1 million in the calendar year (IRS Publication 15). If your top bracket is higher than 22%, withholding can fall short and you may owe more when you file; an estimated payment avoids a surprise.
  • Incentive stock options that are cancelled for cash generally do not get ISO treatment: the payment is taxed like wages, the same as non-qualified options.
  • ESPP shares sold in the deal within 2 years of the offering date or 1 year of purchase are a disqualifying disposition: part of the gain is taxed as ordinary income.
  • Timing: expected closing is in the second half of 2026. If it could fall either side of December 31, the payout lands in a different tax year, which can matter for estimated payments and for bunching deductions.

General rules, not advice for your situation. Your award agreement and the merger agreement control. Full guide: stock options and RSUs in an acquisition →

Source

From the company's SEC filing: DEFM14A (accession 0001104659-26-099364). Last checked against the filing on November 19, 2026. Found an error? Corrections are made the same day; see how we check.

Questions

What will Theravance Biopharma, Inc. shareholders receive?

Under the merger agreement, holders receive $17.00 per share in cash plus a contingent value right (CVR).

What happens to Theravance Biopharma, Inc. stock options and RSUs?

Stock options: cashed out; Unvested RSUs: converted, keep vesting on original schedule (likely); Performance awards (PSUs): mentioned; terms vary

When will the deal close?

The filing expects closing in the second half of 2026. SEC filings show it closed by October 5, 2026.